Literature DB >> 26718313

Overexpression of Fibrinogen-Like Protein 2 Promotes Tolerance in a Fully Mismatched Murine Model of Heart Transplantation.

A Bartczak1,2, A Chruscinski1, M Mendicino3, H Liu1,4, J Zhang1, W He1, A Z Amir1,5, A Nguyen1, R Khattar1, H Sadozai1, C G Lobe6, O Adeyi1, M J Phillips1, L Zhang1, R M Gorczynski1, D Grant1, G A Levy1.   

Abstract

Fibrinogen-like protein 2 (FGL2) is an immunomodulatory protein that is expressed by regulatory T cells (Tregs). The objective of this study was to determine if recombinant FGL2 (rFGL2) treatment or constitutive FGL2 overexpression could promote transplant tolerance in mice. Although rFGL2 treatment prevented rejection of fully mismatched cardiac allografts, all grafts were rejected after stopping treatment. Next, we generated FGL2 transgenic mice (fgl2(Tg) ) that ubiquitously overexpressed FGL2. These mice developed normally and had no evidence of the autoimmune glomerulonephritis seen in fgl2(-/-) mice. Immune characterization showed fgl2(Tg) T cells were hypoproliferative to stimulation with alloantigens or anti-CD3 and anti-CD28 stimulation, and fgl2(Tg) Tregs had increased immunosuppressive activity compared with fgl2(+/+) Tregs. To determine if FGL2 overexpression can promote tolerance, we transplanted fully mismatched cardiac allografts into fgl2(Tg) recipients. Fifty percent of cardiac grafts were accepted indefinitely in fgl2(Tg) recipients without any immunosuppression. Tolerant fgl2(Tg) grafts had increased numbers and proportions of Tregs and tolerant fgl2(Tg) mice had reduced proliferation to donor but not third party antigens. These data show that tolerance in fgl2(Tg) recipients involves changes in Treg and T cell activity that contribute to a higher intragraft Treg-to-T cell ratio and acceptance of fully mismatched allografts. © Copyright 2016 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26718313     DOI: 10.1111/ajt.13696

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  6 in total

1.  Soluble fibrinogen‑like protein 2 levels are decreased in patients with ischemic heart failure and associated with cardiac function.

Authors:  Ya You; Shiyuan Huang; Hui Liu; Cheng Fan; Kun Liu; Zhaohui Wang
Journal:  Mol Med Rep       Date:  2021-06-10       Impact factor: 2.952

2.  Overexpression of fibrinogen-like protein 2 protects against T cell-induced colitis.

Authors:  Agata Bartczak; Jianhua Zhang; Oyedele Adeyi; Achiya Amir; David Grant; Reginald Gorczynski; Nazia Selzner; Andrzej Chruscinski; Gary A Levy
Journal:  World J Gastroenterol       Date:  2017-04-21       Impact factor: 5.742

Review 3.  Soluble fibrinogen like protein 2 (sFGL2), the novel effector molecule for immunoregulation.

Authors:  Xin-Guang Liu; Yu Liu; Feng Chen
Journal:  Oncotarget       Date:  2017-01-10

4.  Fibrinogen-Like Protein 2-Associated Transcriptional and Histopathological Features of Immunological Preeclampsia.

Authors:  Pascale Robineau-Charette; David Grynspan; Samantha J Benton; Jeremiah Gaudet; Brian J Cox; Barbara C Vanderhyden; Shannon A Bainbridge
Journal:  Hypertension       Date:  2020-07-27       Impact factor: 10.190

5.  Overexpression of fibrinogen-like protein 2 alleviates acute rejection in rat models of liver transplantation.

Authors:  Xinxue Zhang; Jun Ma; Han Li; Lin Zhou; Zhe Liu; Shaocheng Lyu; Qiang He; Xianliang Li
Journal:  Ann Transl Med       Date:  2021-03

6.  Soluble fibrinogen-like protein 2 ameliorates acute rejection of liver transplantation in rat via inducing Kupffer cells M2 polarization.

Authors:  Guangrui Pan; Zhengfei Zhao; Chengyong Tang; Liuyue Ding; Zhongtang Li; Daofeng Zheng; Liang Zong; Zhongjun Wu
Journal:  Cancer Med       Date:  2018-05-10       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.